Product Description
Parathyroid hormone (PTH) is a hormone your parathyroid glands release to control calcium levels in your blood. It also controls phosphorus and vitamin D levels. If your body has too much or too little parathyroid hormone, it can cause symptoms related to abnormal blood calcium levels. (Sourced from: https://my.clevelandclinic.org/health/articles/22355-parathyroid-hormone)
Mechanisms of Action: CaSR Antagonist
Novel Mechanism: No
Modality: Peptide/Protein
Route of Administration: Subcutaneous
FDA Designation: None *
Approval Status: Approved
Approved Countries: Austria | Belgium | Croatia | Cyprus | Czech | Denmark | Estonia | European Medicines Agency | Finland | Greece | Hungary | Iceland | Ireland | Italy | Latvia | Lithuania | Norway | Poland | Portugal | Romania | Russia | Slovakia | Spain | Sweden | Thailand | United Kingdom | United States
Approved Indications: None
Known Adverse Events: None
Company: Takeda
Company Location: TOKYO M0 103-8668
Company CEO:
Additonal Commercial Interests: None
Clinical Description
Countries in Clinic: China, Japan, United States
Active Clinical Trial Count: 4
Highest Development Phases
Phase 3: Hypoparathyroidism|Osteoporosis, Postmenopausal
Phase 1: Healthy Volunteers
Trial |
Phase |
Trial Status |
Disease |
Primary Completion Date |
Probability of Success |
|---|---|---|---|---|---|
| JapicCTI-194828 | P3 |
Planned |
Hypoparathyroidism |
2022-05-31 |
|
| TAK-834-1001 | P1 |
Completed |
Healthy Volunteers |
2022-04-15 |
|
| CTR20130667 | P2 |
Active, not recruiting |
Osteoporosis, Postmenopausal |
None |
|
| CTR20212418 | P3 |
Active, not recruiting |
Osteoporosis, Postmenopausal |
None |